Design: Population-based cohort using linked national data
Population: 17,738 patients with renal cell carcinoma in England, 2019–2023
Primary outcome: Treatment within 31 days and delay beyond 62 days of decision to treat
Effect: High-risk timely treatment 83.7% to 64.8%; prolonged delay 3.9% to 9.4%

A population-based study in BJU International, published on 11 October, used linked English data on 7,030 patients with high-risk and 10,708 with low-risk renal cell carcinoma treated between 2019 and 2023.

For a typical high-risk patient, the chance of surgery within 31 days of the decision to treat fell from 83.7% to 64.8%; for low-risk disease, from 71.3% to 47.6%. Delays beyond 62 days more than doubled, from 3.9% to 9.4%. High-risk patients were prioritised (73.6% vs 58.2% treated on time), but prioritisation did not stop the overall decline. Older and more deprived patients waited longer, and once the 31-day standard was breached, the daily chance of surgery dropped sharply.

The finding is from England, but the pattern — a uniform target, then a long tail for those who miss it — applies wherever surgical capacity is stretched. Tracking patients after a target is breached matters as much as the target itself.

Track patients who have passed the waiting-time target; their chance of timely surgery falls quickly after it.
Prioritise high-risk kidney cancers explicitly on surgical lists.
Watch for older and more deprived patients, who waited longest.
Use active surveillance appropriately for small low-risk masses to free capacity.

Why it matters

A single time target hides the patients who fall off its end.

The statistics, in plain English

An adjusted risk ratio of 1.26 means high-risk patients were about a quarter more likely to be treated on time than low-risk patients, after accounting for other differences.